- Report
- February 2026
- 250 Pages
Global
From €3953EUR$4,490USD£3,419GBP
- Report
- August 2025
- 192 Pages
Global
From €3121EUR$3,545USD£2,700GBP
€3468EUR$3,939USD£3,000GBP
- Report
- January 2026
Global
From €4314EUR$4,900USD£3,732GBP
- Report
- February 2026
- 250 Pages
Global
From €3953EUR$4,490USD£3,419GBP
- Report
- November 2025
- 200 Pages
Global
From €6999EUR$7,950USD£6,054GBP
- Report
- November 2025
- 182 Pages
Global
From €3961EUR$4,500USD£3,427GBP
- Report
- July 2025
- 350 Pages
Global
From €4357EUR$4,949USD£3,769GBP
- Report
- November 2025
- 150 Pages
Global
From €4270EUR$4,850USD£3,694GBP
- Report
- February 2026
- 133 Pages
Global
From €3500EUR$4,259USD£3,134GBP
- Report
- June 2025
- 180 Pages
Global
From €3521EUR$4,000USD£3,046GBP
- Report
- July 2022
- 263 Pages
Global
From €1800EUR$2,190USD£1,612GBP
- Report
- November 2021
- 222 Pages
Global
From €2641EUR$3,000USD£2,285GBP
- Report
- July 2022
- 165 Pages
Global
From €5238EUR$5,950USD£4,531GBP
- Report
- March 2024
- 200 Pages
Global
From €3653EUR$4,150USD£3,161GBP
- Report
- July 2023
- 145 Pages
Global
From €2773EUR$3,150USD£2,399GBP
- Drug Pipelines
- April 2025
- 450 Pages
Global
From €4402EUR$5,000USD£3,808GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €1100EUR$1,250USD£952GBP
- Report
- July 2024
- 100 Pages
Global
From €3301EUR$3,750USD£2,856GBP
- Report
- June 2024
- 200 Pages
Global
From €6999EUR$7,950USD£6,054GBP
- Report
- October 2024
- 87 Pages
Spain
From €3081EUR$3,500USD£2,665GBP

The B Cell Maturation Antigen (BCMA) market is a subset of the oncology drugs market. BCMA is a protein found on the surface of B cells, a type of white blood cell. BCMA is a promising target for cancer immunotherapy, as it is expressed on multiple myeloma cells and other B-cell malignancies. BCMA-targeted therapies are designed to stimulate the body's immune system to recognize and attack cancer cells.
BCMA-targeted therapies are being developed by a number of companies, including Amgen, Bristol-Myers Squibb, Celgene, Gilead Sciences, and Novartis. These companies are researching and developing BCMA-targeted therapies for multiple myeloma and other B-cell malignancies. Additionally, several clinical trials are underway to evaluate the safety and efficacy of BCMA-targeted therapies. Show Less Read more